Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q1 2025

Q1 2025 biggest moves
  • WAYWAY

    Waystar

    Sold out

    was 2.3% of portfolio

  • UTHRUTHR

    United Therapeutics

    New

    1.7% of portfolio

  • PFEPFE

    Pfizer

    New

    1.7% of portfolio

  • NBIXNBIX

    Neurocrine Biosciences

    Added 73%

    now 3.3% of portfolio

114 changes in all

Top Holdings123 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

18M$1.3B25.2%——
15 qtrssince 2021-Q3
Unchanged
0
VTRS

Viatris Inc.

24M$209M4.1%$11.16-26.52%
18 qtrssince 2020-Q4
Decreased
0
174.4M$171M3.4%——
5 qtrssince 2024-Q1
Unchanged
0
NBIX

Neurocrine Biosciences, Inc.

1.5M$164.7M3.3%$107.41+2.97%
17 qtrssince 2021-Q1
Increased
84
CNC

Centene Corporation

2.7M$162.2M3.2%$67.92-10.62%
22 qtrssince 2019-Q4
Unchanged
0
OSCR

Oscar Health, Inc.

11.8M$155.2M3.1%$11.50+13.97%
6 qtrssince 2023-Q4
Increased
55
MRUS
MRUSDelisted

MERUS N V

3.2M$133.6M2.6%——
14 qtrssince 2021-Q4
Increased
55
SPRY

ARS Pharmaceuticals, Inc.

10.5M$132.3M2.6%$8.53+47.48%
10 qtrssince 2022-Q4
Unchanged
0
??
ACCOLADE INCDelisted
Bond
132.6M$130.6M2.6%——
12 qtrssince 2022-Q2
Unchanged
0
110M$126.9M2.5%——
3 qtrssince 2024-Q3
Unchanged
0
RVMD

Revolution Medicines, Inc.

3.3M$117.3M2.3%$28.01+26.23%
21 qtrssince 2020-Q1
Increased
52
70M$114.5M2.3%——
4 qtrssince 2024-Q2
Unchanged
0
AHCO

AdaptHealth Corp.

9.7M$105.3M2.1%$18.05-39.93%
22 qtrssince 2019-Q4
Unchanged
0
INDV
INDVDelisted

INDIVIOR PLC

10.6M$100.7M2.0%$8.28-10.74%
3 qtrssince 2024-Q3
Increased
56
BKD

Brookdale Senior Living Inc.

15.6M$97.7M1.9%$4.41+41.94%
22 qtrssince 2019-Q4
Unchanged
0
ALHC

Alignment Healthcare, Inc.

4.6M$85M1.7%$6.20+200.50%
8 qtrssince 2023-Q2
Decreased
0
UTHR

United Therapeutics Corporation

275,226$84.8M1.7%$308.270.00%
1 qtr
New
68
PFE

Pfizer, Inc.

3.3M$84.8M1.7%$22.510.00%
1 qtr
New
68
NAMS

NewAmsterdam Pharma Company N.V.

4.1M$84M1.7%$25.01-18.15%
5 qtrssince 2024-Q1
Decreased
0
CPRX
CPRXDelisted

CATALYST PHARMACEUTICALS INC

3.4M$83M1.6%——
11 qtrssince 2022-Q3
Increased
51
$5.1B
AUM
123
Positions
Q1 2025
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2023-Q4$5,415,638,75919.3189129063%
2024-Q1$5,748,069,8946.13835504533%
2024-Q2$6,010,510,6294.56571927342%
2024-Q3$6,692,805,83111.3517011135%
2024-Q4$5,280,006,191-21.1092279632%
2025-Q1$5,064,779,427-4.07625969013%
Activity profile
$ moved · Q1'25
New37%Increased15%Decreased17%Exited30%
Composition
Equity vs derivatives
Equity>99%Puts<1%Calls0%
Holding period
Avg 2.1 years
<1Q20%1-4Q7%1-2Y21%2Y+52%

Deerfield Management Company, L.P. manages $5.1B across 123 positions as of Q1 2025. Top holdings: NUVL (25.2%), VTRS (4.1%), INTEGRA LIFESCIENCES HLDGS C (3.4%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$5B
NUVL25.19%
VTRS4.13%
INTEGRA LIFE3.38%
NBIX3.25%
CNC3.20%
OSCR3.06%
MRUS2.64%
SPRY2.61%
ACCOLADE INC2.58%
ALNYLAM PHAR2.50%
Other2.32%

Portfolio allocation by GICS sector

Sectors8
Healthcare99.17%
Unknown0.79%
Real Estate0.01%
Technology0.01%
Consumer Cyclical0.01%
Energy0.01%
Communication Services0.00%
Industrials0.00%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used